|
[1]
|
李红, 王乃弋(2004). 论执行功能及其发展研究. 心理科学, 27(2), 426-430.
|
|
[2]
|
彭聃龄(2001). 普通心理学 (修订版). 北京: 北京师范大学出版社.
|
|
[3]
|
杨治良(2011). 漫谈人类记忆的研究. 心理科学, (1), 249-250.
|
|
[4]
|
Addy, N., & Levin, E. D. (2002). Nicotine Interactions with Haloperidol, Clozapine and Risperidone and Working Memory Function in Rats. Neuropsychopharmacology, 27, 534-541.[CrossRef]
|
|
[5]
|
Aman, M. G., Hollway, J. A., Leone, S., Masty, J., Lindsay, R., Nash, P., & Arnold, L. E. (2009). Effects of Risperidone on Cognitive-Motor Performance and Motor Movements in Chronically Medicated Children. Research in Developmental Disabilities, 30, 386-396.[CrossRef] [PubMed]
|
|
[6]
|
Anderson, I. M., Haddad, P. M., & Scott, J. (2012). Bipolar Disorder. BMJ, 345, e8508.[CrossRef] [PubMed]
|
|
[7]
|
Atti, A. R., Ferrari Gozzi, B., Zuliani, G., Bernabei, V., Scudellari, P., Berardi, D., Menchetti, M. et al. (2014). A Systematic Review of Metabolic Side Effects Related to the Use of Antipsychotic Drugs in Dementia. International Psychogeriatrics, 26, 19-37.
|
|
[8]
|
Barak, S., & Weiner, I. (2011). Putative Cognitive Enhancers in Preclinical Models Related to Schizophrenia: The Search for an Elusive Target. Pharmacology Biochemistry and Behavior, 99, 164-189.[CrossRef] [PubMed]
|
|
[9]
|
Bardgett, M. E., Baum, K. T., O’Connell, S. M., Lee, N. M., & Hon, J. C. (2006). Effects of Risperidone on Locomotor Activity and Spatial Memory in Rats with Hippocampal Damage. Neuropharmacology, 51, 1156-1162.[CrossRef] [PubMed]
|
|
[10]
|
Bloechliger, M., Ruegg, S., Jick, S. S., Meier, C. R., & Bodmer, M. (2015). Antipsychotic Drug Use and the Risk of Seizures: Follow-Up Study with a Nested Case-Control Analysis. CNS Drugs, 29, 591-603.[CrossRef] [PubMed]
|
|
[11]
|
Bowie, C. R., McLaughlin, D., Carrion, R. E., Auther, A. M., & Cornblatt, B. A. (2012). Cognitive Changes Following Antidepressant or Antipsychotic Treatment in Adolescents at Clinical Risk for Psychosis. Schizophrenia Research, 137, 110-117.[CrossRef] [PubMed]
|
|
[12]
|
Burda, K., Czubak, A., Kus, K., Nowakowska, E., Ratajczak, P., & Zin, J. (2011). Influence of Aripiprazole on the Antidepressant, Anxiolytic and Cognitive Functions of Rats. Pharmacological Reports, 63, 898-907.[CrossRef]
|
|
[13]
|
Burda-Malarz, K., Kus, K., Ratajczak, P., Czubak, A., Nowakowska, E., Jedrzejewski, L., & Sadowski, C. (2014). Evaluation of Antidepressant and Memory-Improving Efficacy of Aripiprazole and Fluoxetine in Alcohol-Preferring Rats. Acta Neuropsychiatrica, 26, 112-119.[CrossRef] [PubMed]
|
|
[14]
|
Carli, M., Calcagno, E., Mainolfi, P., Mainini, E., & Invernizzi, R. W. (2011). Effects of Aripiprazole, Olanzapine, and Haloperidol in a Model of Cognitive Deficit of Schizophrenia in Rats: Relationship with Glutamate Release in the Medial Prefrontal Cortex. Psychopharmacology, 214, 639-652.[CrossRef] [PubMed]
|
|
[15]
|
Castro, C. C., Dos Reis-Lunardelli, E. A., Schmidt, W. J., Coitinho, A. S., & Izquierdo, I. (2007). Clozapine and Olanzapine but Not Risperidone Impair the Pre-Frontal Striatal System in Relation to Egocentric Spatial Orientation in a Y-Maze. Current Neurovascular Research, 4, 235-239.[CrossRef] [PubMed]
|
|
[16]
|
Chang, S. W., McGuire, J. F., Walkup, J. T., Woods, D. W., Scahill, L., Wilhelm, S. et al. (2018). Neurocognitive Correlates of Treatment Response in Children with Tourette’s Disorder. Psychiatry Research, 261, 464-472.[CrossRef] [PubMed]
|
|
[17]
|
Choi, Y. K., Gardner, M. P., & Tarazi, F. I. (2009). Effects of Risperidone on Glutamate Receptor Subtypes in Developing Rat Brain. European Neuropsychopharmacology, 19, 77-84.[CrossRef] [PubMed]
|
|
[18]
|
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018). What Is the Risk-Benefit Ratio of Long-Term Antipsychotic Treatment in People with Schizophrenia? World Psychiatry, 17, 149-160.[CrossRef] [PubMed]
|
|
[19]
|
Dahoun, T., Trossbach, S. V., Brandon, N. J., Korth, C., & Howes, O. D. (2017). The Impact of Disrupted-in-Schizophrenia 1 (DISC1) on the Dopaminergic System: A Systematic Review. Translational Psychiatry, 7, e1015.[CrossRef] [PubMed]
|
|
[20]
|
Demirkaya, S. K., Aksu, H., & Ozgur, B. G. (2017). A Retrospective Study of Long Acting Risperidone Use to Support Treatment Adherence in Youth with Conduct Disorder. Clinical Psychopharmacology and Neuroscience, 15, 328-336.[CrossRef] [PubMed]
|
|
[21]
|
Deziel, R. A., Ryan, C. L., & Tasker, R. A. (2015). Ischemic Lesions Localized to the Medial Prefrontal Cortex Produce Selective Deficits in Measures of Executive Function in Rats. Behavioural Brain Research, 293, 54-61.[CrossRef] [PubMed]
|
|
[22]
|
Dumontheil, I. (2014). Development of Abstract Thinking during Childhood and Adolescence: The Role of Rostrolateral Prefrontal Cortex. Developmental Cognitive Neuroscience, 10, 57-76.[CrossRef] [PubMed]
|
|
[23]
|
Egerton, A., Ahmad, R., Hirani, E., & Grasby, P. M. (2008). Modulation of Striatal Dopamine Release by 5-HT2A and 5-HT2C Receptor Antagonists: [11C]Raclopride PET Studies in the Rat. Psychopharmacology (Berl), 200, 487-496.[CrossRef] [PubMed]
|
|
[24]
|
Elsworth, J. D., Groman, S. M., Jentsch, J. D., Valles, R., Shahid, M., Wong, E. et al. (2012). Asenapine Effects on Cognitive and Monoamine Dysfunction Elicited by Subchronic Phencyclidine Administration. Neuropharmacology, 62, 1442-1452.[CrossRef] [PubMed]
|
|
[25]
|
Fatouros-Bergman, H., Cervenka, S., Flyckt, L., Edman, G., & Farde, L. (2014). Meta-Analysis of Cognitive Performance in Drug-Naive Patients with Schizophrenia. Schizophrenia Research, 158, 156-162.[CrossRef] [PubMed]
|
|
[26]
|
Forray, C., & Buller, R. (2017). Challenges and Opportunities for the Development of New Antipsychotic Drugs. Biochemical Pharmacology, 143, 10-24.[CrossRef] [PubMed]
|
|
[27]
|
Goldberg, T. E., Goldman, R. S., Burdick, K. E., Malhotra, A. K., Lencz, T., Patel, R. C. et al. (2007). Cognitive Improvement after Treatment with Second-Generation Antipsychotic Medications in First-Episode Schizophrenia: Is It a Practice Effect? Archives of General Psychiatry, 64, 1115-1122.
|
|
[28]
|
Guo, X., Zhai, J., Wei, Q., Twamley, E. W., Jin, H., Fang, M. et al. (2011). Neurocognitive Effects of First- and Second-Generation Antipsychotic Drugs in Early-Stage Schizophrenia: A Naturalistic 12-Month Follow-Up Study. Neuroscience Letters, 503, 141-146.[CrossRef] [PubMed]
|
|
[29]
|
Hartz, I., Skurtveit, S., Steffenak, A. K., Karlstad, O., & Handal, M. (2016). Psychotropic Drug Use among 0 - 17 Year Olds during 2004-2014: A Nationwide Prescription Database Study. BMC Psychiatry, 16, 12.[CrossRef] [PubMed]
|
|
[30]
|
Holzer, B., Lopes, V., & Lehman, R. (2013). Combination Use of Atomoxetine Hydrochloride and Olanzapine in the Treatment of Attention-Deficit/Hyperactivity Disorder with Comorbid Disruptive Behavior Disorder in Children and Adolescents 10 - 18 Years of Age. Journal of Child and Adolescent Psychopharmacology, 23, 415-418.[CrossRef] [PubMed]
|
|
[31]
|
Hori, H., Yoshimura, R., Katsuki, A., Hayashi, K., Ikenouchi-Sugita, A., Umene-Nakano, W., & Nakamura, J. (2012). Several Prescription Patterns of Antipsychotic Drugs Influence Cognitive Functions in Japanese Chronic Schizophrenia Patients. International Journal of Psychiatry in Clinical Practice, 16, 138-142.[CrossRef] [PubMed]
|
|
[32]
|
Hsu, C. W., Lee, S. Y., & Wang, L. J. (2017). Comparison of the Effectiveness of Brand-Name and Generic Antipsychotic Drugs for Treating Patients with Schizophrenia in Taiwan. Schizophrenia Research, 193, 107-113.
|
|
[33]
|
Hsu, S. W., Chiang, P. H., Chang, Y. C., Lin, J. D., Tung, H. J., & Chen, C. Y. (2014). Trends in the Use of Psychotropic Drugs in People with Intellectual Disability in Taiwan: A Nationwide Outpatient Service Study, 1997-2007. Research in Developmental Disabilities, 35, 364-372.[CrossRef] [PubMed]
|
|
[34]
|
Husa, A. P., Moilanen, J., Murray, G. K., Marttila, R., Haapea, M., Rannikko, I. et al. (2017). Lifetime Antipsychotic Medication and Cognitive Performance in Schizophrenia at Age 43 Years in a General Population Birth Cohort. Psychiatry Research, 247, 130-138.[CrossRef] [PubMed]
|
|
[35]
|
Hutchings, E. J., Waller, J. L., & Terry Jr., A. V. (2013). Differential Long-Term Effects of Haloperidol and Risperidone on the Acquisition and Performance of Tasks of Spatial Working and Short-Term Memory and Sustained Attention in Rats. Journal of Pharmacology and Experimental Therapeutics, 347, 547-556.[CrossRef] [PubMed]
|
|
[36]
|
Keedy, S. K., Reilly, J. L., Bishop, J. R., Weiden, P. J., & Sweeney, J. A. (2015). Impact of Antipsychotic Treatment on Attention and Motor Learning Systems in First-Episode Schizophrenia. Schizophrenia Bulletin, 41, 355-365.[CrossRef] [PubMed]
|
|
[37]
|
Keefe, R. S., Bilder, R. M., Davis, S. M., Harvey, P. D., Palmer, B. W., Gold, J. M. et al. (2007). Neurocognitive Effects of Antipsychotic Medications in Patients with Chronic Schizophrenia in the CATIE Trial. Archives of General Psychiatry, 64, 633-647.
|
|
[38]
|
Levin, E. D., McClernon, F. J., & Rezvani, A. H. (2006). Nicotinic Effects on Cognitive Function: Behavioral Characterization, Pharmacological Specification, and Anatomic Localization. Psychopharmacology (Berl), 184, 523-539.[CrossRef] [PubMed]
|
|
[39]
|
Loy, J. H., Merry, S. N., Hetrick, S. E., & Stasiak, K. (2017). Atypical Antipsychotics for Disruptive Behaviour Disorders in Children and Youths. Cochrane Database of Systematic Reviews, 8, CD008559.[CrossRef]
|
|
[40]
|
Maeda, K., Lerdrup, L., Sugino, H., Akazawa, H., Amada, N., McQuade, R. D. et al. (2014). Brexpiprazole II: Antipsychotic-Like and Procognitive Effects of A Novel Serotonin-Dopamine Activity Modulator. Journal of Pharmacology and Experimental Therapeutics, 350, 605-614.[CrossRef] [PubMed]
|
|
[41]
|
Maher, A. R., & Theodore, G. (2012). Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics. Journal of Managed Care Pharmacy, 18, S1-S20.[CrossRef]
|
|
[42]
|
Maia, T. V., & Frank, M. J. (2017). An Integrative Perspective on the Role of Dopamine in Schizophrenia. Biological Psychiatry, 81, 52-66.[CrossRef] [PubMed]
|
|
[43]
|
Marston, H. M., Young, J. W., Martin, F. D., Serpa, K. A., Moore, C. L., Wong, E. H. et al. (2009). Asenapine Effects in Animal Models of Psychosis and Cognitive Function. Psychopharmacology (Berl), 206, 699-714.[CrossRef] [PubMed]
|
|
[44]
|
Martinez, V., & Sarter, M. (2008). Detection of the Moderately Beneficial Cognitive Effects of Low-Dose Treatment with Haloperidol or Clozapine in an Animal Model of the Attentional Impairments of Schizophrenia. Neuropsychopharmacology, 33, 2635-2647.[CrossRef] [PubMed]
|
|
[45]
|
McLean, S. L., Neill, J. C., Idris, N. F., Marston, H. M., Wong, E. H., & Shahid, M. (2010). Effects of Asenapine, Olanzapine, and Risperidone on Psychotomimetic-Induced Reversal-Learning Deficits in the Rat. Behavioural Brain Research, 214, 240-247.[CrossRef] [PubMed]
|
|
[46]
|
Millier, A., Schmidt, U., Angermeyer, M. C., Chauhan, D., Murthy, V., Toumi, M., & Cadi-Soussi, N. (2014). Humanistic Burden in Schizophrenia: A Literature Review. Journal of Psychiatric Research, 54, 85-93.[CrossRef] [PubMed]
|
|
[47]
|
Moe, A. A. K., Medely, G. A., Reeks, T., Burne, T. H. J., & Eyles, D. W. (2017). Short- and Long-Term Effects of Risperidone on Catalepsy Sensitisation and Acquisition of Conditioned Avoidance Response: Adolescent vs Adult Rats. Pharmacological Research, 121, 1-13.[CrossRef] [PubMed]
|
|
[48]
|
Moe, R. O., Nordgreen, J., Janczak, A. M., Bakken, M., Spruijt, B. M., & Jensen, P. (2014). Anticipatory and Foraging Behaviors in Response to Palatable Food Reward in Chickens: Effects of Dopamine D2 Receptor Blockade and Domestication. Physiology & Behavior, 133, 170-177.[CrossRef] [PubMed]
|
|
[49]
|
Moran-Gates, T., Grady, C., Shik Park, Y., Baldessarini, R. J., & Tarazi, F. I. (2007). Effects of Risperidone on Dopamine Receptor Subtypes in Developing rat Brain. European Neuropsychopharmacology, 17, 448-455.[CrossRef] [PubMed]
|
|
[50]
|
Moritz, S., Andreou, C., Klingberg, S., Thoering, T., & Peters, M. J. (2013). Assessment of Subjective Cognitive and Emotional Effects of Antipsychotic Drugs. Effect by Defect? Neuropharmacology, 72, 179-186.[CrossRef] [PubMed]
|
|
[51]
|
Mott, A. M., Nunes, E. J., Collins, L. E., Port, R. G., Sink, K. S., Hockemeyer, J. et al. (2009). The Adenosine A(2A) Antagonist MSX-3 Reverses the Effects of the Dopamine Antagonist Haloperidol on Effort-Related Decision Making in a T-Maze Cost/Benefit Procedure. Psychopharmacology (Berl), 204, 103-112.[CrossRef] [PubMed]
|
|
[52]
|
Murai, T., Nakako, T., Ikejiri, M., Ishiyama, T., Taiji, M., & Ikeda, K. (2013). Effects of Lurasidone on Executive Function in Common Marmosets. Behavioural Brain Research, 246, 125-131.[CrossRef] [PubMed]
|
|
[53]
|
Nikiforuk, A., & Popik, P. (2013). Amisulpride Promotes Cognitive Flexibility in Rats: The Role of 5-HT7 Receptors. Behavioural Brain Research, 248, 136-140.[CrossRef] [PubMed]
|
|
[54]
|
Ning, H., Cao, D., Wang, H., Kang, B., Xie, S., & Meng, Y. (2017). Effects of Haloperidol, Olanzapine, Ziprasidone, and PHA-543613 on Spatial Learning and Memory in the Morris Water Maze Test in Naive and MK-801-Treated Mice. Brain and Behavior, 7, e00764.[CrossRef] [PubMed]
|
|
[55]
|
Owen, M. J., Sawa, A., & Mortensen, P. B. (2016). Schizophrenia. The Lancet, 388, 86-97.[CrossRef]
|
|
[56]
|
Pandina, G. J., Zhu, Y., & Cornblatt, B. (2009). Cognitive Function with Long-Term Risperidone in Children and Adolescents with Disruptive Behavior Disorder. Journal of Child and Adolescent Psychopharmacology, 19, 749-756.[CrossRef] [PubMed]
|
|
[57]
|
Pflibsen, L., Stang, K. A., Sconce, M. D., Wilson, V. B., Hood, R. L., Meshul, C. K., & Mitchell, S. H. (2015). Executive Function Deficits and Glutamatergic Protein Alterations in a Progressive 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mouse Model of Parkinson’s Disease. Journal of Neuroscience Research, 93, 1849-1864.[CrossRef] [PubMed]
|
|
[58]
|
Pierre, J. M. (2005). Extrapyramidal Symptoms with Atypical Antipsychotics: Incidence, Prevention and Management. Drug Safety, 28, 191-208.[CrossRef] [PubMed]
|
|
[59]
|
Ratajczak, P., Kus, K., Jarmuszkiewicz, Z., Wozniak, A., Cichocki, M., & Nowakowska, E. (2013). Influence of Aripiprazole and Olanzapine on Behavioral Dysfunctions of Adolescent Rats Exposed to Stress in Perinatal Period. Pharmacological Reports, 65, 30-43.[CrossRef]
|
|
[60]
|
Remberk, B., Namyslowska, I., & Rybakowski, F. (2012). Cognition and Communication Dysfunctions in Early-Onset Schizophrenia: Effect of Risperidone. Progress in Neu-ro-Psychopharmacology & Biological Psychiatry, 39, 348-354.[CrossRef] [PubMed]
|
|
[61]
|
Russo, E., Citraro, R., Davoli, A., Gallelli, L., Di Paola, E. D., & De Sarro, G. (2013). Ameliorating Effects of Aripiprazole on Cognitive Functions and Depressive-Like Behavior in a Genetic Rat Model of Absence Epilepsy and Mild-Depression Comorbidity. Neuropharmacology, 64, 371-379.[CrossRef] [PubMed]
|
|
[62]
|
Sacarny, A., Barnett, M. L., Le, J., Tetkoski, F., Yokum, D., & Agrawal, S. (2018). Effect of Peer Comparison Letters for High-Volume Primary Care Prescribers of Quetiapine in Older and Disabled Adults: A Randomized Clinical Trial. JAMA Psychiatry.
|
|
[63]
|
Satoh, M., Obara, T., Nishigori, H., Ooba, N., Morikawa, Y., Ishikuro, M. et al. (2016). Prescription Trends in Children with Pervasive Developmental Disorders: A Claims Data-Based Study in Japan. World Journal of Pediatrics, 12, 443-449.[CrossRef] [PubMed]
|
|
[64]
|
Scheggi, S., Pelliccia, T., Ferrari, A., De Montis, M. G., & Gambarana, C. (2015). Impramine, Fluoxetine and Clozapine Differently Affected Reactivity to Positive and Negative Stimuli in a Model of Motivational Anhedonia in Rats. Neuroscience, 291, 189-202.[CrossRef] [PubMed]
|
|
[65]
|
Stip, E., Cherbal, A., Luck, D., Zhornitsky, S., Bentaleb, L. A., & Lungu, O. (2017). A Neuroimaging Study of Emotion-Cognition Interaction in Schizophrenia: The Effect of Ziprasidone Treatment. Psychopharmacology (Berl), 234, 1045-1058.[CrossRef] [PubMed]
|
|
[66]
|
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018). Pharmacotherapy for Generalized Anxiety Disorder in Adult and Pediatric Patients: An Evidence-Based Treatment Review. Expert Opinion on Pharmacotherapy, 19, 1057-1070.[CrossRef] [PubMed]
|
|
[67]
|
Taylor, G. T., Smith, S. E., & Kirchhoff, B. A. (2013). Differential Effects of Antipsychotics on Lateral Bias and Social Attention in Female Rats. Psychopharmacology (Berl), 225, 453-460.[CrossRef] [PubMed]
|
|
[68]
|
Tort, A. B., Souza, D. O., & Lara, D. R. (2006). Theoretical Insights into the Mechanism of Action of Atypical Antipsychotics. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 30, 541-548.[CrossRef] [PubMed]
|
|
[69]
|
Unschuld, P. G., Liu, X., Shanahan, M., Margolis, R. L., Bassett, S. S., Brandt, J. et al. (2013). Prefrontal Executive Function Associated Coupling Relates to Huntington’s Disease Stage. Cortex, 49, 2661-2673.[CrossRef] [PubMed]
|
|
[70]
|
Vernon, A. C., Natesan, S., Modo, M., & Kapur, S. (2011). Effect of Chronic Antipsychotic Treatment on Brain Structure: A Serial Magnetic Resonance Imaging Study with ex Vivo and Postmortem Confirmation. Biological Psychiatry, 69, 936-944.[CrossRef] [PubMed]
|
|
[71]
|
Vigen, C. L., Mack, W. J., Keefe, R. S., Sano, M., Sultzer, D. L., Stroup, T. S. et al. (2011). Cognitive Effects of Atypical Antipsychotic Medications in Patients with Alzheimer’s Disease: Outcomes from CATIE-AD. American Journal of Psychiatry, 168, 831-839.[CrossRef] [PubMed]
|
|
[72]
|
Vita, A., De Peri, L., Deste, G., Barlati, S., & Sacchetti, E. (2015). The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-Analysis and Meta-Regression of Longitudinal Magnetic Resonance Imaging Studies. Biological Psychiatry, 78, 403-412.[CrossRef] [PubMed]
|
|
[73]
|
Xu, S., Gullapalli, R. P., & Frost, D. O. (2015). Olanzapine Antipsychotic Treatment of Adolescent Rats Causes Long Term Changes in Glutamate and GABA Levels in the Nucleus Accumbens. Schizophrenia Research, 161, 452-457.[CrossRef] [PubMed]
|
|
[74]
|
Xue, F., Chen, Y. C., Zhou, C. H., Wang, Y., Cai, M., Yan, W. J. et al. (2017). Risperidone Ameliorates Cognitive Deficits, Promotes Hippocampal Proliferation, and Enhances Notch Signaling in a Murine Model of Schizophrenia. Pharmacology Biochemistry and Behavior, 163, 101-109.[CrossRef] [PubMed]
|
|
[75]
|
Yeh, C. B., Huang, Y. S., Tang, C. S., Wang, L. J., Chou, W. J., Chou, M. C., & Chen, C. K. (2014). Neurocognitive Effects of Aripiprazole in Adolescents and Young Adults with Schizophrenia. Nordic Journal of Psychiatry, 68, 219-224.[CrossRef] [PubMed]
|
|
[76]
|
Zhang, C., Fang, Y., & Xu, L. (2014). Glutamate Receptor 1 Phosphorylation at Serine 845 Contributes to the Therapeutic Effect of Olanzapine on Schizophrenia-Like Cognitive Impairments. Schizophrenia Research, 159, 376-384.[CrossRef] [PubMed]
|